Brian Callaghan1, Kevin Kerber2, Kenneth M Langa2, Mousumi Banerjee2, Ann Rodgers2, Ryan McCammon2, James Burke2, Eva Feldman2. 1. From the University of Michigan (B.C., K.K., K.M.L., M.B., A.R., R.M., J.B., E.F.); and the VA Center for Clinical Management Research (K.M.L., J.B.), Ann Arbor, MI. bcallagh@med.umich.edu. 2. From the University of Michigan (B.C., K.K., K.M.L., M.B., A.R., R.M., J.B., E.F.); and the VA Center for Clinical Management Research (K.M.L., J.B.), Ann Arbor, MI.
Abstract
OBJECTIVE: To evaluate longitudinal patient-oriented outcomes in peripheral neuropathy over a 14-year time period including time before and after diagnosis. METHODS: The 1996-2007 Health and Retirement Study (HRS)-Medicare Claims linked database identified incident peripheral neuropathy cases (ICD-9 codes) in patients ≥65 years. Using detailed demographic information from the HRS and Medicare claims, a propensity score method identified a matched control group without neuropathy. Patient-oriented outcomes, with an emphasis on self-reported falls, pain, and self-rated health (HRS interview), were determined before and after neuropathy diagnosis. Generalized estimating equations were used to assess differences in longitudinal outcomes between cases and controls. RESULTS: We identified 953 peripheral neuropathy cases and 953 propensity-matched controls. The mean (SD) age was 77.4 (6.7) years for cases, 76.9 (6.6) years for controls, and 42.1% had diabetes. Differences were detected in falls 3.0 years before neuropathy diagnosis (case vs control; 32% vs 25%, p = 0.008), 5.0 years for pain (36% vs 27%, p = 0.002), and 5.0 years for good to excellent self-rated health (61% vs 74%, p < 0.0001). Over time, the proportion of fallers increased more rapidly in neuropathy cases compared to controls (p = 0.002), but no differences in pain (p = 0.08) or self-rated health (p = 0.9) were observed. CONCLUSIONS: In older persons, differences in falls, pain, and self-rated health can be detected 3-5 years prior to peripheral neuropathy diagnosis, but only falls deteriorates more rapidly over time in neuropathy cases compared to controls. Interventions to improve early peripheral neuropathy detection are needed, and future clinical trials should incorporate falls as a key patient-oriented outcome.
OBJECTIVE: To evaluate longitudinal patient-oriented outcomes in peripheral neuropathy over a 14-year time period including time before and after diagnosis. METHODS: The 1996-2007 Health and Retirement Study (HRS)-Medicare Claims linked database identified incident peripheral neuropathy cases (ICD-9 codes) in patients ≥65 years. Using detailed demographic information from the HRS and Medicare claims, a propensity score method identified a matched control group without neuropathy. Patient-oriented outcomes, with an emphasis on self-reported falls, pain, and self-rated health (HRS interview), were determined before and after neuropathy diagnosis. Generalized estimating equations were used to assess differences in longitudinal outcomes between cases and controls. RESULTS: We identified 953 peripheral neuropathy cases and 953 propensity-matched controls. The mean (SD) age was 77.4 (6.7) years for cases, 76.9 (6.6) years for controls, and 42.1% had diabetes. Differences were detected in falls 3.0 years before neuropathy diagnosis (case vs control; 32% vs 25%, p = 0.008), 5.0 years for pain (36% vs 27%, p = 0.002), and 5.0 years for good to excellent self-rated health (61% vs 74%, p < 0.0001). Over time, the proportion of fallers increased more rapidly in neuropathy cases compared to controls (p = 0.002), but no differences in pain (p = 0.08) or self-rated health (p = 0.9) were observed. CONCLUSIONS: In older persons, differences in falls, pain, and self-rated health can be detected 3-5 years prior to peripheral neuropathy diagnosis, but only falls deteriorates more rapidly over time in neuropathy cases compared to controls. Interventions to improve early peripheral neuropathy detection are needed, and future clinical trials should incorporate falls as a key patient-oriented outcome.
Authors: Brian C Callaghan; Kevin A Kerber; Lynda L Lisabeth; Lewis B Morgenstern; Ruth Longoria; Ann Rodgers; Paxton Longwell; Eva L Feldman Journal: JAMA Neurol Date: 2014-09 Impact factor: 18.302
Authors: Stefano Volpato; Caroline Blaum; Helaine Resnick; Luigi Ferrucci; Linda P Fried; Jack M Guralnik Journal: Diabetes Care Date: 2002-04 Impact factor: 19.112
Authors: Sang Soo Kim; Jong Chul Won; Hyuk Sang Kwon; Chong Hwa Kim; Ji Hyun Lee; Tae Sun Park; Kyung Soo Ko; Bong Yun Cha Journal: Diabetes Res Clin Pract Date: 2013-12-25 Impact factor: 5.602
Authors: L Vileikyte; M Peyrot; J S Gonzalez; R R Rubin; A P Garrow; D Stickings; C Waterman; J S Ulbrecht; P R Cavanagh; A J M Boulton Journal: Diabetologia Date: 2009-04-18 Impact factor: 10.122
Authors: Edward W Gregg; Paul Sorlie; Ryne Paulose-Ram; Qiuping Gu; Mark S Eberhardt; Michael Wolz; Vicki Burt; Lester Curtin; Michael Engelgau; Linda Geiss Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: Caroline A Abbott; Rayaz A Malik; Ernest R E van Ross; Jai Kulkarni; Andrew J M Boulton Journal: Diabetes Care Date: 2011-08-18 Impact factor: 19.112
Authors: Rachel E Ward; Paolo Caserotti; Jane A Cauley; Robert M Boudreau; Bret H Goodpaster; Aaron I Vinik; Anne B Newman; Elsa S Strotmeyer Journal: Aging Dis Date: 2015-11-27 Impact factor: 6.745
Authors: Brian C Callaghan; Rong Xia; Mousumi Banerjee; Nathalie de Rekeneire; Tamara B Harris; Anne B Newman; Suzanne Satterfield; Ann V Schwartz; Aaron I Vinik; Eva L Feldman; Elsa S Strotmeyer Journal: Diabetes Care Date: 2016-03-10 Impact factor: 19.112
Authors: Nicola Veronese; Giacomo Siri; Alberto Cella; Stefania Maggi; Ekaterini Zigoura; Matteo Puntoni; Lee Smith; Clarissa Musacchio; Antonella Barone; Carlo Sabbà; Francesco Vallone; Alberto Pilotto Journal: J Am Med Dir Assoc Date: 2019-11-25 Impact factor: 4.669
Authors: Brian C Callaghan; Evan Reynolds; Mousumi Banerjee; Ericka Chant; Emily Villegas-Umana; Eva L Feldman Journal: Mayo Clin Proc Date: 2020-07 Impact factor: 7.616